17.1 Midwifery Primary Care Scope & Hypertension Management
Key Takeaways
- ACC/AHA categories are normal below 120 and below 80, elevated at 120 to 129 with diastolic below 80, stage 1 at 130 to 139 or 80 to 89, and stage 2 at 140 or higher or 90 or higher.
- Diagnosis of hypertension requires confirmation with out-of-office measurement, either ambulatory or home monitoring, to exclude white-coat hypertension.
- Midwifery primary care scope includes health maintenance, cancer screening, immunization, and management of uncomplicated hypertension, dyslipidemia, type 2 diabetes, and hypothyroidism.
- Preconception counseling to transition teratogenic medications before organogenesis is an explicit component of midwifery primary care.
- Lifestyle change, led by weight reduction, the DASH eating pattern, and sodium restriction, produces clinically meaningful blood pressure reduction and is started in every category.
The scope of practice for the Certified Nurse-Midwife (CNM) encompasses comprehensive primary healthcare services for individuals from adolescence through postmenopause. Rather than being confined strictly to pregnancy and childbirth, the Midwifery Model of Care integrates wellness promotion, acute illness management, and the longitudinal management of chronic disease. In ambulatory women's health settings, nurse-midwives frequently encounter asymptomatic or newly emerging cardiometabolic and endocrine conditions. Autonomous, evidence-based management of these chronic disorders—coupled with a vigilant understanding of reproductive risks, teratogenic pharmacotherapy, and preconception optimization—is a cornerstone of safe clinical practice tested on the American Midwifery Certification Board (AMCB) examination.
Midwifery Scope in Lifespan Primary Care
Per the American College of Nurse-Midwives (ACNM) Core Competencies for Basic Midwifery Practice, certified nurse-midwives are independent primary care providers. Midwifery primary care includes:
- Routine health maintenance, age-appropriate cancer screenings (cervical, breast, colorectal), and immunizations across the lifespan.
- Diagnosis and primary management of uncomplicated chronic conditions (e.g., essential hypertension, dyslipidemia, type 2 diabetes mellitus, Hashimoto hypothyroidism).
- Identification of complex multisystem pathology necessitating interprofessional consultation, collaboration, or referral to physician specialists.
- Preconception counseling to optimize maternal physiology and transition teratogenic medications before organogenesis commences.
Hypertension: ACC/AHA Staging, Diagnosis & Lifestyle Interventions
Cardiovascular disease remains the leading cause of death among women in the United States. Chronic hypertension affects an estimated 30% to 40% of reproductive-age and perimenopausal individuals. The 2025 AHA/ACC high blood pressure guideline, which replaced the 2017 ACC/AHA document, retains the same standardized clinical categories for blood pressure in non-pregnant adults.
AHA/ACC Blood Pressure Categories (Non-Pregnant Adults, Unchanged in 2025)
| Blood Pressure Category | Systolic Blood Pressure (mm Hg) | Operator | Diastolic Blood Pressure (mm Hg) |
|---|---|---|---|
| Normal | < 120 | and | < 80 |
| Elevated | 120 – 129 | and | < 80 |
| Stage 1 Hypertension | 130 – 139 | or | 80 – 89 |
| Stage 2 Hypertension | ≥ 140 | or | ≥ 90 |
| Hypertensive Crisis | > 180 | and/or | > 120 |
Diagnostic Confirmation & Excluding White-Coat Hypertension
An isolated elevated in-office blood pressure reading must never be used to establish a definitive diagnosis of hypertension, unless the patient presents with hypertensive emergency (severe elevation accompanied by acute target-organ damage) or initial screening reveals blood pressure ≥180/≥120 mm Hg.
- Office Protocol: Confirm elevation across at least two separate clinical encounters (separated by 1 to 4 weeks), obtaining an average of ≥2 seated readings per visit after 5 minutes of quiet rest, using a calibrated sphygmomanometer and appropriately sized cuff (bladder encircling 75%–100% of arm circumference).
- Out-of-Office Confirmation: To exclude white-coat hypertension (elevated clinic readings with normal ambulatory readings) or detect masked hypertension (normal clinic readings with elevated home readings), clinical guidelines require Out-of-Office Blood Pressure Monitoring prior to initiating lifelong pharmacotherapy:
- Home Blood Pressure Monitoring (HBPM): The patient records twice-daily readings (morning and evening, two readings each time) for 7 consecutive days. An average HBPM ≥130/80 mm Hg confirms hypertension.
- 24-Hour Ambulatory Blood Pressure Monitoring (ABPM): The gold standard diagnostic modality. Hypertension is confirmed by a 24-hour mean BP ≥125/75 mm Hg, daytime mean ≥130/80 mm Hg, or nighttime mean ≥110/65 mm Hg.
Evidence-Based Lifestyle Interventions
Lifestyle modifications form the non-negotiable foundation for all stages of hypertension and can lower systolic BP by 4 to 11 mm Hg per intervention:
- DASH Dietary Pattern: Diet rich in fruits, vegetables, whole grains, and low-fat dairy, with reduced saturated and total fat (~11 mm Hg systolic reduction in hypertensive patients).
- Dietary Sodium Reduction: Restrict sodium intake to <1,500 mg/day (or achieve a minimum reduction of at least 1,000 mg/day; ~5–6 mm Hg systolic reduction).
- Potassium Supplementation: Target dietary potassium intake of 3,500 to 5,000 mg/day through potassium-rich foods (bananas, avocados, sweet potatoes, spinach), unless contraindicated by chronic kidney disease or concurrent potassium-sparing medications.
- Structured Aerobic & Resistance Exercise: At least 150 minutes per week of moderate-intensity aerobic physical activity (or 75 minutes of vigorous activity), supplemented by dynamic resistance exercise 2 to 3 days per week (~4–8 mm Hg reduction).
- Weight Reduction: Aim for normal BMI (18.5–24.9 kg/m²). Blood pressure decreases by approximately 1 mm Hg per 1 kg of body weight lost.
- Alcohol Moderation: Limit intake to ≤1 standard drink daily for women (or complete cessation; ~4 mm Hg reduction).
Workup of Newly Diagnosed Hypertension
Confirming the diagnosis is only half the visit. Every newly diagnosed patient needs a baseline assessment for target-organ damage, secondary causes, and coexisting cardiovascular risk:
| Test | What it screens for |
|---|---|
| Basic metabolic panel (sodium, potassium, creatinine with eGFR, calcium) | Renal impairment; unprovoked hypokalemia suggests primary aldosteronism |
| Urinalysis and urine albumin-to-creatinine ratio | Glomerular disease and early hypertensive kidney damage |
| Fasting lipid panel and fasting glucose or HbA1c | Coexisting dyslipidemia and diabetes, both of which change the treatment threshold |
| TSH | Thyroid disease as a secondary and reversible cause |
| CBC | Anemia, polycythemia |
| 12-lead ECG | Left ventricular hypertrophy as evidence of long-standing disease |
| Calculated 10-year cardiovascular risk | Determines whether stage 1 hypertension warrants medication |
Screen for secondary hypertension rather than simply escalating drugs when the presentation is atypical: onset before age 30, abrupt onset or acceleration of previously controlled pressure, hypertension resistant to three agents, unprovoked hypokalemia, target-organ damage out of proportion to the measured pressure, or a suggestive history. The common reversible causes in this population are primary aldosteronism, obstructive sleep apnea, renal parenchymal or renovascular disease, thyroid disease, and drug effects — combined hormonal contraceptives, NSAIDs, decongestants, stimulants, and excess alcohol. Resistant hypertension means blood pressure above goal despite three agents at maximally tolerated doses including a diuretic, or pressure controlled only on four or more agents.
Treatment Thresholds and Drug Selection
The 2025 AHA/ACC high blood pressure guideline, which supersedes the 2017 document, keeps the categories and the ≥130/80 mm Hg diagnostic threshold unchanged but changes how treatment decisions are made:
- Risk is now estimated with the PREVENT equations, which replaced the pooled cohort equations and incorporate kidney function and social factors, estimating both 10-year and 30-year total cardiovascular risk.
- Overall treatment goal is <130/80 mm Hg for most adults, with encouragement toward <120/80 where it can be achieved safely.
- Stage 1 (130–139/80–89): start medication when 10-year risk is ≥7.5%, or when clinical cardiovascular disease, diabetes, or chronic kidney disease is present. Below that risk, treat with lifestyle change and reassess in 3 to 6 months, adding medication if the pressure has not fallen below 130/80.
- Stage 2 (≥140/90): begin two first-line agents of different classes, preferably as a single-pill fixed-dose combination.
First-line classes are thiazide-type diuretics (chlorthalidone is preferred over hydrochlorothiazide for its longer duration and outcome data), dihydropyridine calcium channel blockers (amlodipine), ACE inhibitors, and ARBs. Never combine an ACE inhibitor with an ARB. Beta-blockers are not first-line for uncomplicated hypertension; they are reserved for a compelling indication such as ischemic heart disease, heart failure with reduced ejection fraction, or arrhythmia.
The Reproductive-Age Overlay
This is the point where midwifery primary care differs from general primary care, and it is heavily tested. Before prescribing for any patient who could become pregnant, ask about pregnancy intention, and revisit the question at every renewal:
- ACE inhibitors, ARBs, direct renin inhibitors, and atenolol are contraindicated in pregnancy. Renin–angiotensin blockade in the second and third trimesters causes fetal renal dysgenesis, oligohydramnios, pulmonary hypoplasia, and calvarial hypoplasia.
- Pregnancy-compatible agents are labetalol, extended-release nifedipine, and methyldopa. A reproductive-age patient who is not using reliable contraception is better started on one of these at the outset than converted urgently after a positive pregnancy test.
- Spironolactone is antiandrogenic and is avoided in pregnancy.
- For chronic hypertension in pregnancy, current guidance treats to a target of <140/90 mm Hg, and low-dose aspirin prophylaxis is started between 12 and 16 weeks for patients who meet the risk criteria covered in the preeclampsia chapter.
- Document a preconception plan in the chart for every reproductive-age patient on an antihypertensive, so that the medication transition happens before organogenesis rather than after a missed period.
A 46-year-old has office blood pressures of 136/84 and 134/86 at two visits. She has no diabetes, no known cardiovascular disease, normal renal function, and an estimated 10-year cardiovascular risk of 4 percent. What is the correct management?